Addressing fatty tissue in quantitative susceptibility mapping of human knee cartilage
Magnetic Resonance Materials in Physics, Biology and Medicine · 2025
DOI: 10.1007/s10334-025-01280-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magnetic Resonance Materials in Physics, Biology and Medicine, 2025. Verfasst von Cornelia Säll und 5 weiteren Autor:innen. Beteiligte Einrichtung: Imaging and Physiology, Skåne University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Cartilage, Articular, Knee Joint, Magnetic Resonance Imaging, Adipose Tissue. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish governmental funding of clinical research (ALF), Vetenskapsrådet, Reumatikerförbundet.
Abstract (Originalsprache)
Objective
To evaluate the effects of excluding fatty tissue in QSM of human knee cartilage. Materials and methods Gradient echo images from 18 knee-healthy volunteers were acquired, from which chemical shift corrected field perturbation maps were calculated. Based on these, QSM maps were reconstructed using morphology enabled dipole inversion and one of three masking alternatives: (1) excluding no tissue, (2) excluding bone marrow, and (3) excluding all fatty tissues. The slope of a linear regression [ppm/%] between susceptibility values and the relative distance from the bone surfaces was used as a measurement of contrast between cartilage layers. The average differences in slopes between methods are reported with 95% confidence intervals.
Results
The expected susceptibility differences between cartilage layers from literature were observed for all tested reconstruction techniques. However, smaller slopes (average difference (confidence interval)) were detected when either all fatty tissue (− 0.090 (− 0.121, − 0.059) ppm/%) or bone marrow (− 0.088 (− 0.121, − 0.055) ppm/%) was excluded from reconstruction.
Discussion
All tested methods result in adequate image quality in QSM of knee cartilage. However, exclusion of fatty tissue decreased the susceptibility contrast between cartilage layers. Assuming that phase contributions from chemical shift are addressed, inclusion of fatty tissue may be preferable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Imaging and Physiology, Skåne University Hospital, Lund, Sweden.
- Department of Medical Radiation Physics, Lund University, Lund, Sweden.
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden.
- Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
- Imaging and Physiology, Skåne University Hospital, Lund, Sweden. pernilla.peterson@med.lu.se.
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden. pernilla.peterson@med.lu.se.
Förderung
- Swedish governmental funding of clinical research (ALF)
- Vetenskapsrådet
- Reumatikerförbundet
- Hjärnfonden
- Greta och Johan Kocks stiftelser
- Alfred Österlunds Stiftelse
- Stiftelsen Konung Gustaf V:s 80-årsfond
- Stiftelsen för Bistånd åt Rörelsehindrade i Skåne
Zitieren
APA
Säll, C., Lind, E., Einarsson, E., Turkiewicz, A., Englund, M., & Peterson, P. (2025). Addressing fatty tissue in quantitative susceptibility mapping of human knee cartilage. Magnetic Resonance Materials in Physics, Biology and Medicine. https://doi.org/10.1007/s10334-025-01280-0
Vancouver
Säll C, Lind E, Einarsson E, Turkiewicz A, Englund M, Peterson P. Addressing fatty tissue in quantitative susceptibility mapping of human knee cartilage. Magnetic Resonance Materials in Physics, Biology and Medicine. 2025. doi:10.1007/s10334-025-01280-0
BibTeX
@article{Sll2025,
author = {Säll, Cornelia and Lind, Emelie and Einarsson, Emma and Turkiewicz, Aleksandra and Englund, Martin and Peterson, Pernilla},
title = {Addressing fatty tissue in quantitative susceptibility mapping of human knee cartilage},
journal = {Magnetic Resonance Materials in Physics, Biology and Medicine},
year = {2025},
doi = {10.1007/s10334-025-01280-0}
}
EUVIMED